Introduction: chronic peripheral arterial disease (PAD) seems to be a "rediscovered" pathology nowadays, brought into spotlight by its strong correlation with other signifi cant cardiovascular disorders.
Objectives: to sustain a real benefi t from treatment with i.v. prostaglandins (PG) in PAD patients and to directly compare the currently used PG: alprostadil and iloprost.
Method: open, non-randomized cohort study, with placebo group ("classical therapy") reviewing 615 PAD patients with therapeutic approach during 2003-2012 period, divided in 3 subgroups: "classical" therapy; "classical" therapy + iloprost; "classical" therapy + alprostadil; patients with Burger's disease were excluded; multiple factor analysis with statistical results inserted.
Results: clear domination of male gender patients, with older female gender patients (p.0.001); smoking like major risk factor in male and in all patients (p< 0.0001); 124 patients underwent angiography .
Conclusion: a real improvement in the clinical status of patients receiving i.v. prostaglandin therapy with no diff erences between genders, diabetic and non-diabetic patients; alprostadil seems better than iloprost.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486158 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Paediatric Otogenic Cerebral Venous Thrombosis: Diagnostic Approach and Therapeutic Management - A Five-Year Single-Centre Experience.
Otolaryngol Pol
January 2025
Department of Pediatric Otolaryngology, Medical University of Warsaw, Poland.
<b>Introduction:</b> Central venous thrombosis (CVT) represents a well-documented complication of acute otitis media (AOM) and acute mastoiditis (AM). Despite widespread antibiotic utilization, which has significantly reduced the incidence of severe AOM/AM complications, recent years have witnessed an increasing frequency of thrombotic complications in pediatric patients, not invariably presenting with classical neurological manifestations.<b>Aim:</b> This study aimed to investigate the potential correlation between COVID-19 infection and increased CVT incidence, while sharing therapeutic experiences, given the absence of standardized treatment protocols for otogenic CVT in pediatric populations.
View Article and Find Full Text PDFThe Impact of Microvascular Decompression on Pain Management in Trigeminal Neuralgia: Clinical Insights.
Cureus
December 2024
Department of Surgery, Hawler Teaching Hospital, Erbil, IRQ.
Background and aim Trigeminal neuralgia (TN) is a chronic disorder accompanied by recurrent severe pain affecting the face. Many medical regimens are used in the treatment of trigeminal neuralgia. Neurosurgery intervention is the best treatment option, especially with the failure of medical therapy.
View Article and Find Full Text PDFUnlabelled: Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, in part resulting from cellular heterogeneity that supports overall tumorigenicity. Cancer associated fibroblasts (CAF) are key determinants of PDAC biology and response to systemic therapy. While CAF subtypes have been defined, the effects of patient-specific CAF heterogeneity and plasticity on tumor cell behavior remain unclear.
View Article and Find Full Text PDFProteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.
J Hematol Oncol
January 2025
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Background: Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral replication in the cancer cells was not observed. The combination with proteasome inhibitors (PIs) has shown to enhance RV therapeutic activity, but the mechanisms of action have not been fully elucidated.
View Article and Find Full Text PDFAdvancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!